Glass House Brands Inc. GLAS PHARMA
Company Overview
Glass House Brands Inc., together with its subsidiaries, operates as an integrated cannabis company in the United States. It operates through three segments: Retail; Wholesale Biomass; and Cannabis-Related Consumer Packaged Goods. The Retail segment owns, and operates retail cannabis stores, and dispensary operation management services. The Wholesale Biomass segment includes propagation, nursery, flowering canopy, dries, processes, and distributes cannabis biomass. The Cannabis-Related Consumer Packaged Goods segment manufactures, extracts, infuse, conversion, packaging, and distributes cannabis products. The company cultivates, manufactures, and distributes cannabis bulk flowers and trims to wholesalers; and consumer packaged goods to third-party retail stores in California. It also offers raw cannabis, cannabis oil, and cannabis consumer goods; edibles; flower jars and bags; single, multi-pack, and infused pre-rolls; tinctures; biomass for distributors; and online payment processing, in-store pickup and home delivery services for adult-use and medicinal-use customers. The company serves its cannabis products under the Glass House Farms, PLUS, Allswell, REEFORM, and Mama Sue brand names. Glass House Brands Inc. was founded in 2015 and is headquartered in Long Beach, California.
Why Investors Should Care
Revenue has grown at a 28.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $181.98M (-9.4% YoY); net profit $-29.66M.
- Trailing 12 Months Year-on-year growth — revenue -1.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 28.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 28.95% |
| 1 Year: | -1.20% |
Stock Price Performance
| 1 Year: | +10.73% |
| 6 Months: | +4.50% |
| 3 Months: | -36.38% |
| 1 Month: | -17.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 28.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 38.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GLAS Glass House Brands Inc. PHARMA | 8.36 | -10.45 | $735.66M | 0.00% | -5.21% | -28.58% | 28.95% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 44.82M | 59.87M | 38.44M | 38.85M | 38.85M |
| Cost of Revenue | - | 24.75M | 27.94M | 26.69M | 25.65M | 25.65M |
| Gross Profit | - | 20.07M | 31.93M | 11.76M | 13.21M | 13.21M |
| Operating Expenses | - | 21.27M | 21.29M | 23.14M | 25.89M | 25.89M |
| Operating Income | - | -1.21M | 10.64M | -11.38M | -12.68M | -12.68M |
| EBITDA | - | -967.00K | 19.54M | -5.30M | -7.46M | -7.46M |
| Interest Expense | - | 2.28M | 1.92M | 1.82M | 1.04M | 1.04M |
| Pretax Income | - | -7.08M | 13.71M | -11.12M | -12.53M | -12.53M |
| Tax Provision | - | 2.93M | 4.97M | 1.07M | 2.97M | 2.97M |
| Net Income | - | -10.01M | 8.67M | -12.29M | -15.97M | -15.50M |
| Diluted EPS | - | -0.13 | 0.05 | -0.19 | -0.19 | -0.18 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 84.87M | 160.84M | 200.90M | 181.98M |
| Cost of Revenue | - | 64.16M | 79.87M | 103.50M | 105.02M |
| Gross Profit | - | 20.71M | 80.97M | 97.39M | 76.96M |
| Operating Expenses | - | 71.25M | 77.68M | 85.36M | 91.59M |
| Operating Income | - | -50.54M | 3.29M | 12.04M | -14.63M |
| EBITDA | - | -17.44M | -63.67M | 35.45M | 5.80M |
| Interest Expense | - | 7.61M | 9.82M | 9.18M | 7.06M |
| Pretax Income | - | -37.35M | -88.12M | 11.22M | -17.02M |
| Tax Provision | - | -4.39M | 9.94M | 10.50M | 11.93M |
| Net Income | - | -32.90M | -98.27M | 519.00K | -29.66M |
| Diluted EPS | - | -0.83 | -1.37 | 0.01 | -0.35 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 350.63M | 303.77M | 310.50M | 318.56M |
| Current Assets | - | 38.89M | 49.22M | 66.10M | 67.75M |
| Cash & Equivalents | - | 11.14M | 29.52M | 33.92M | 19.85M |
| Inventory | - | 10.95M | 8.84M | 14.25M | 26.23M |
| Receivables | - | 4.79M | 3.98M | 5.22M | 4.42M |
| Total Liabilities | - | 129.49M | 158.54M | 146.45M | 221.46M |
| Current Liabilities | - | 54.00M | 87.36M | 66.48M | 37.96M |
| Long Term Debt | - | 62.62M | 56.51M | 50.55M | 68.63M |
| Total Debt | - | 73.88M | 75.13M | 69.20M | 74.57M |
| Total Equity | - | 168.86M | 89.76M | 116.24M | 73.94M |
| Shares Outstanding | - | 68.22M | 70.94M | 76.91M | 81.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -40.78M | 23.22M | 28.39M | 11.45M |
| Investing Cash Flow | - | -29.20M | -12.71M | -10.29M | -27.74M |
| Financing Cash Flow | - | 30.06M | 7.87M | -13.70M | 2.72M |
| Capital Expenditure | - | -27.77M | -12.31M | -10.29M | -27.18M |
| Free Cash Flow | - | -68.55M | 10.91M | 18.10M | -15.73M |
| Net Change in Cash | - | -39.92M | 18.38M | 4.40M | -13.57M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 24.4% | 50.3% | 48.5% | 42.3% |
| Operating Margin % | - | -59.6% | 2.0% | 6.0% | -8.0% |
| Net Margin % | - | -38.8% | -61.1% | 0.3% | -16.3% |
| ROE % | - | -19.5% | -109.5% | 0.4% | -40.1% |
| ROCE % | - | -17.0% | 1.5% | 4.9% | -5.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Park West Asset Management LLC | 5.67% | 5.18M | $41.30M |
| 2 | Western Standard, LLC | 2.99% | 2.73M | $21.75M |
| 3 | Nomura Holdings Inc. | 2.50% | 2.28M | $18.20M |
| 4 | Cantor Fitzgerald, L.P. | 1.48% | 1.35M | $10.76M |
| 5 | Wellington Management Group, LLP | 1.25% | 1.15M | $9.13M |
| 6 | AdvisorShares Investments, LLC | 0.93% | 850.00K | $6.77M |
| 7 | Clear Street Group Inc. | 0.90% | 825.00K | $6.58M |
| 8 | Marex Group Ltd. | 0.82% | 750.00K | $5.98M |
| 9 | Hudson Bay Capital Management Lp | 0.82% | 750.00K | $5.98M |
| 10 | Grizzlyrock Capital, LLC | 0.67% | 611.00K | $4.87M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GLAS
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9fd2dYUGpyZ0haQ2NidUZZMW5sdGwycm8zbi1PSFBDSEFtalczLWpqNVNhOGUwYnVDQ1RObmp5OF9nT0h1bDVrdVBmdVhfdVB1?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Glass House Brands (GLAS) insider lines up NYSE share sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQVDBsVkVlYmNJc3VjQzVxWHRCX1lyTjlqV3pXTTg4RkpqdjRwX0dkUDNhSXZnbFFhZmRhOEd0QjE5RWlNU1o3cmxpUS1aQ3VoV05QdVY5UXgzb3MtRmdRWmRhcjNyMUowVHA1UDVaV21PWk9jc0x5blNYdzR2VktLLUtORVFaUE5xeUtMeU…
Glass House Brands Reports Second Quarter 2026 Financial Results - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNMjlMTFVJOHAtZVMzOTlVaEwxd2Q0UWNSZmhYdF9qVjg2VFFDNVRUekdaeXFSNENqV1h0MHBMNHhVbGlLdmhVUUxCQmljZ0d0SXIyRHhrcmFxQWxtM1VsOWVCYkd3Z0dvTThtc1VqVTFVUEJNX2QzcEVSWW9Db1Q2SkJuRElmZ0xILTNzRn…
Glass House Brands Announces Uplist to NYSE - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOcGRpcXVxZDVBak8tV2ppSW5kN2pPdVk1d3hBTEtLZTJIZHpuZ2RGM1hVbFBDWmYyZkx4RDE4azhfXzhZeXdNRHBJNGotaXd3WkRydE1ORll6bFIwUEVyOXBPeF91UFlNV3VtOGVSc3pRWmF3WF91YkdGNUpTSkpJMUpuWEFBTTNHdVl6dU…
4 Best Glass Stocks for 2026 and How to Invest - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNdjNNQzdHZVZxNWNDM0p5TGdQM09CZDB6NDQ0akJjd3o1ejQybVI1ZU5zX0w3czNuTzQxaDZJVWEtU2RvaHc2WGV6SmxGNkxpR1dLUEJveEd5RUxDZ0JKOWtIckZTZDRCZ1l5aU1QdkpMZUVRVlkyUjQwY0dzZkVHSkxxNE1jY1J1TWc?oc…
Is Glass House’s NYSE Uplisting And Medical Pivot Reshaping The Investment Case For GLAS? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPXzZpVGxGVjRzcmsxNE1aRDNGbHdpdHdiWVQtVjVMNXdQY1hMc2tmVUlIaDBYeUhEblQyMWRYZG1ZQTFHeUJmbnp4cklxNHl4cXl4Y2NDSkdNSHNnU2l6QVE3aGstZUs0aFAzRlNwczBOejB2UXRNVWpQMl9SbXB5Tzh5dzlZN0lxb3NndW…
GLAS — Frequently Asked Questions
What is the current share price of Glass House Brands Inc. (GLAS)?
As of 2026-09-19 21:16 PDT, Glass House Brands Inc. (GLAS) trades at $8.36 on NYSE. Its 52-week range is $5.31 to $13.58.
What is the market capitalisation of GLAS?
Glass House Brands Inc. (GLAS) has a market capitalisation of $735.66M on NYSE.
What is the P/E ratio of GLAS?
GLAS trades at a trailing price-to-earnings (P/E) ratio of -10.45. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 9.77.
What is the return on equity (ROE) of GLAS?
GLAS has a return on equity (ROE) of -28.58%. Its return on capital employed (ROCE) is -5.21%.
Is GLAS a good stock to buy?
This page provides a data-driven analysis of Glass House Brands Inc. (GLAS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.